In one paragraphArticle in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
33 authors.
Raymond C KoehlerDepartment of Anesthesiology and Critical Care Medicine Johns Hopkins University Baltimore MD USA.ORCID 0000-0002-5890-9992 Karni BedirianDepartment of Population Health Science and Policy Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai New York NY USA.
Mu-Hsun ChenDepartment of Population Health Science and Policy Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai New York NY USA.ORCID 0000-0002-5111-1582 Yanrong ShiDepartment of Anesthesiology and Critical Care Medicine Johns Hopkins University Baltimore MD USA.ORCID 0000-0002-3144-5569 Suyi CaoDepartment of Anesthesiology and Critical Care Medicine Johns Hopkins University Baltimore MD USA.ORCID 0000-0002-0230-1232 Brooklyn D AveryDepartment of Anesthesiology and Critical Care Medicine Johns Hopkins University Baltimore MD USA.ORCID 0009-0009-7093-7580 Senthilkumar S KaruppagounderDepartment of Neurology Johns Hopkins University Baltimore MD USA.
Kazi AkhterDepartment of Radiology Johns Hopkins University Baltimore MD USA.
Márcio A DinizDepartment of Population Health Science and Policy Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai New York NY USA.ORCID 0000-0002-2427-7843 Jessica LambDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute Keck School of Medicine at University of Southern California Los Angeles CA USA.ORCID 0000-0002-0342-9983 Karisma A NagarkattiDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute Keck School of Medicine at University of Southern California Los Angeles CA USA.ORCID 0009-0007-3526-1365 Anjali ChauhanDepartment of Neurology, McGovern Medical School University of Texas HSC Houston TX USA.ORCID 0000-0002-9825-8100 Jaroslaw AronowskiDepartment of Neurology, McGovern Medical School University of Texas HSC Houston TX USA.ORCID 0000-0002-9256-7973 Louise D McCulloughDepartment of Neurology, McGovern Medical School University of Texas HSC Houston TX USA.ORCID 0000-0002-8050-1686 Andreia Lopes de MoraisDepartment of Radiology Harvard Medical School, Massachusetts General Hospital Charlestown MA USA.
Xuyan JinDepartment of Radiology Harvard Medical School, Massachusetts General Hospital Charlestown MA USA.ORCID 0009-0003-1923-4923 Cenk AyataDepartment of Neurology Harvard Medical School, Massachusetts General Hospital Charlestown MA USA.ORCID 0000-0002-3644-6042 Mariia KumskovaDepartment of Internal Medicine, Division of Hematology, Oncology and Blood & Bone Marrow Transplantation, Carver College of Medicine University of Iowa Iowa City IA USA.ORCID 0000-0002-2477-3011 Rakesh B PatelDepartment of Internal Medicine, Division of Hematology, Oncology and Blood & Bone Marrow Transplantation, Carver College of Medicine University of Iowa Iowa City IA USA.ORCID 0000-0001-9727-9738 Anil K ChauhanDepartment of Internal Medicine, Division of Hematology, Oncology and Blood & Bone Marrow Transplantation, Carver College of Medicine University of Iowa Iowa City IA USA.ORCID 0000-0001-8554-0898 Enrique C LeiraDepartment of Neurology, Carver College of Medicine University of Iowa Iowa City IA USA.ORCID 0000-0003-3695-2946 Pradip K KamatDepartment of Neurology Medical College of Georgia, Augusta University Augusta Georgia USA.ORCID 0000-0002-0376-2284 Mohammad B KhanDepartment of Neurology Medical College of Georgia, Augusta University Augusta Georgia USA.ORCID 0000-0001-8231-1256 Krishnan M DhandapaniDepartment of Neurology Medical College of Georgia, Augusta University Augusta Georgia USA.ORCID 0000-0001-7044-1117 David C HessDepartment of Neurology Medical College of Georgia, Augusta University Augusta Georgia USA.ORCID 0000-0002-8345-9153 Basavaraju G SanganahalliDepartment of Radiology and Biomedical Imaging Yale University School of Medicine New Haven CT USA.ORCID 0000-0002-0851-6621 Patrick D LydenDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute Keck School of Medicine at University of Southern California Los Angeles CA USA.ORCID 0000-0001-6170-4042 SPAN investigators [Link]
Funding
Stroke Preclinical Assessment Network (SPAN) – Tacilizumab for treatment of acute ischemic strokeU01NS113451 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARONOWSKI, JAROSLAW · 2019 to 2021
$1.1MNINDS NIH HHS U01 NS113451
6 · The paper itselfAbstract
backgroundThe Stroke Preclinical Assessment Network tested 6 therapeutic interventions initiated at the time of reperfusion after focal ischemic stroke in young mice, aging mice, obese mice, and spontaneously hypertensive rats. This randomized, controlled trial was conducted across 6 sites with concealed treatment and blinded neurobehavior assessments. The trial had an adaptive design with preset levels of efficacy and futility interrogated after each of 4 stages. The primary outcome was turning preference on the corner test at 1 month. The PARP (poly(ADP-ribose) polymerase) inhibitor, veliparib, was considered futile after the second stage when pooling all animal models (
methodsA secondary analysis was performed to evaluate veliparib treatment on primary and secondary outcomes in individual subgroup models.
resultsIntravenous injection of veliparib at reperfusion failed to show a benefit on the corner test at 7 or 30 days of recovery in young mice, obese mice, or spontaneously hypertensive rats. However, in aging mice (15-18 months old), veliparib significantly improved performance on the corner test at 7 (
conclusionsVeliparib improved functional outcome in aging mice. Because ischemic stroke predominantly occurs in the aging population, further research into the benefit of PARP inhibitors in aged animal models of stroke is warranted.
Indexed as
BenzimidazolesIschemic StrokePoly(ADP-ribose) Polymerase InhibitorsStrokeAge FactorsAnimalsBehavior, AnimalDisease Models, AnimalMaleMiceMice, Inbred C57BLRatsRats, Inbred SHRRisk FactorsBenzimidazolesPoly(ADP-ribose) Polymerase Inhibitorsveliparibagingmiddle cerebral artery occlusionobesitypoly(ADP‐ribose) polymerasepreclinical trialspontaneously hypertensive ratveliparib
Identifiers
PMID40996065
PMCPMC12684482
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390